In vitro biomarker discovery in the parasitic flatworm Fasciola hepatica for monitoring chemotherapeutic treatment

Russell Mark Morphew, Neil Douglas MacKintosh, Elizabeth Helen Hart, Mark Prescott, E. James LaCourse, Peter Michael Brophy

Research output: Contribution to journalArticlepeer-review

17 Citations (SciVal)
169 Downloads (Pure)

Abstract

The parasitic flatworm Fasciola hepatica is a global food security risk. With no vaccines, the sustainability of triclabendazole (TCBZ) is threatened by emerging resistance. F. hepatica excretory/secretory (ES) products can be detected in host faeces and used to estimate TCBZ success and failure. However, there are no faecal based molecular diagnostics dedicated to assessing drug failure or resistance to TCBZ in the field. Utilising in vitro maintenance and sub-proteomic approaches two TCBZ stress ES protein response fingerprints were identified: markers of non-killing and lethal doses. This study provides candidate protein/peptide biomarkers to validate for detection of TCBZ failure and resistance.
Original languageEnglish
Pages (from-to)85-99
Number of pages15
JournalEuPA Open Proteomics
Volume3
Early online date12 Mar 2014
DOIs
Publication statusPublished - Jun 2014

Keywords

  • Proteomics
  • Biomarkers
  • Triclabendazole
  • Calreticulin

Fingerprint

Dive into the research topics of 'In vitro biomarker discovery in the parasitic flatworm Fasciola hepatica for monitoring chemotherapeutic treatment'. Together they form a unique fingerprint.

Cite this